© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Key opinion leaders review clinical cases in triple-negative breast cancer, focusing on recent advances, treatment options, and clinical trials impacting the treatment.
May 27th 2021
Elizabeth Mittendorf, MD, PhD, reviews the case of a 53-year-old woman with PD-L1+ TNBC breast cancer and the panel discusses relevant clinical trial data.
Experts in breast cancer discuss efficacy data from the IMpassion130 clinical trial.
The panel of experts review the study design and key efficacy data of the KEYNOTE-355 trial.
The panel discusses treatment options and considerations for a 53-year-old woman with PD-L1+ triple-negative breast cancer.
June 3rd 2021
Elizabeth Mittendorf, MD, PhD, presents the case of a 34-year-old woman with PD-L1–positive triple-negative breast cancer.
Experts in the management of breast cancer review some treatment considerations surrounding the use of PARP inhibitors in BRCA1/2–positive triple-negative breast cancer.
Experts in the management of breast cancer review clinical trial data using PARP inhibitors in the treatment of BRCA1/2-mutated TNBC.
June 10th 2021
Elizabeth Mittendorf, MD, PhD, and Ruta Rao, MD, present the case of a 48-year-old woman with stage T2N1 TNBC.
Pathologist David G. Hicks, MD, discusses the impact of residual disease in breast cancer treatment outcomes.
The panel of experts share their treatment recommendations for patients with residual disease after an incomplete response to TNBC therapy.